

Anders Åsberg

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2695407/publications.pdf>

Version: 2024-02-01

237
papers

8,332
citations

53660

45
h-index

56606

83
g-index

241
all docs

241
docs citations

241
times ranked

8138
citing authors

#	ARTICLE	IF	CITATIONS
1	Short- and long-term effects of body weight loss following calorie restriction and gastric bypass on CYP3A4 activity in a non-randomized three-armed controlled trial. <i>Clinical and Translational Science</i> , 2022, 15, 221-233.	1.5	13
2	Atorvastatin population pharmacokinetics in a real-life setting: Influence of genetic polymorphisms and association with clinical response. <i>Clinical and Translational Science</i> , 2022, 15, 667-679.	1.5	8
3	Kidney Transplant Recipient Behavior During the Early COVID-19 Pandemic: A National Survey Study in Norway. <i>Kidney Medicine</i> , 2022, 4, 100389.	1.0	2
4	Use of Statins in Kidney Transplant Recipients in Norway. <i>International Journal of Environmental Research and Public Health</i> , 2022, 19, 1370.	1.2	0
5	A Comorbidity Index and Pretransplant Physical Status Predict Survival in Older Kidney Transplant Recipients: A National Prospective Study. <i>Transplantation Direct</i> , 2022, 8, e1307.	0.8	6
6	Drug Disposition Protein Quantification in Matched Human Jejunum and Liver From Donors With Obesity. <i>Clinical Pharmacology and Therapeutics</i> , 2022, 111, 1142-1154.	2.3	16
7	Inflammation in the early phase after kidney transplantation is associated with increased long-term all-cause mortality. <i>American Journal of Transplantation</i> , 2022, 22, 2016-2027.	2.6	8
8	Endothelial Dysfunction and 6-Year Risk of Mortality in Kidney Transplant Recipients. <i>Transplantation Direct</i> , 2022, 8, e1262.	0.8	1
9	Short- and long-term effects of body weight, calorie restriction and gastric bypass on CYP1A2, CYP2C19 and CYP2C9 activity. <i>British Journal of Clinical Pharmacology</i> , 2022, 88, 4121-4133.	1.1	13
10	High Plasma Oxalate Levels Early After Kidney Transplantation Are Associated With Impaired Long-Term Outcomes. <i>Transplant International</i> , 2022, 35, 10240.	0.8	3
11	Fourth dose of the SARS-CoV-2 vaccine in kidney transplant recipients with previously impaired humoral antibody response. <i>American Journal of Transplantation</i> , 2022, 22, 2704-2706.	2.6	24
12	MO985: Physical Function Trajectories Predict Patient Survival in Older Recipients of Deceased Donor Kidneys. <i>Nephrology Dialysis Transplantation</i> , 2022, 37, .	0.4	0
13	FC 111: A Comorbidity Index and Pretransplant Physical Status Predict Survival in Older Kidney Transplant Recipients. <i>Nephrology Dialysis Transplantation</i> , 2022, 37, .	0.4	0
14	Demonstrating Benefit-Risk Profiles of Novel Therapeutic Strategies in Kidney Transplantation: Opportunities and Challenges of Real-World Evidence. <i>Transplant International</i> , 2022, 35, 10329.	0.8	5
15	MO952: Risk Factors of Post Transplantation Diabetes Mellitus After Kidney Transplantation. <i>Nephrology Dialysis Transplantation</i> , 2022, 37, .	0.4	0
16	Anticoagulation and safety of renal transplant biopsy. <i>Clinical Transplantation</i> , 2022, 36, e14715.	0.8	0
17	A Hybrid Model Associating Population Pharmacokinetics with Machine Learning: A Case Study with Iohexol Clearance Estimation. <i>Clinical Pharmacokinetics</i> , 2022, 61, 1157-1165.	1.6	13
18	Correlations between 4 β -hydroxycholesterol and hepatic and intestinal CYP3A4: protein expression, microsomal ex vivo activity, and in vivo activity in patients with a wide body weight range. <i>European Journal of Clinical Pharmacology</i> , 2022, 78, 1289-1299.	0.8	9

#	ARTICLE	IF	CITATIONS
19	Correlation of Body Weight and Composition With Hepatic Activities of Cytochrome P450 Enzymes. <i>Journal of Pharmaceutical Sciences</i> , 2021, 110, 432-437.	1.6	31
20	Recovery of kidney function in patients treated with maintenance dialysis—a report from the ERA-EDTA Registry. <i>Nephrology Dialysis Transplantation</i> , 2021, 36, 1078-1087.	0.4	1
21	Proteomics-Informed Prediction of Rosuvastatin Plasma Profiles in Patients With a Wide Range of Body Weight. <i>Clinical Pharmacology and Therapeutics</i> , 2021, 109, 762-771.	2.3	15
22	Patient selection for islet or solid organ pancreas transplantation: experiences from a multidisciplinary outpatient-clinic approach. <i>Endocrine Connections</i> , 2021, 10, 230-239.	0.8	3
23	Tacrolimus Measured in Capillary Volumetric Microsamples in Pediatric Patients—A Cross-Validation Study. <i>Therapeutic Drug Monitoring</i> , 2021, 43, 371-375.	1.0	16
24	Blood Pressure Treatment in Kidney Transplant Recipients—Can We Improve?. <i>Transplantation Direct</i> , 2021, 7, e688.	0.8	1
25	Prednisolone and Prednisone Pharmacokinetics in Adult Renal Transplant Recipients. <i>Therapeutic Drug Monitoring</i> , 2021, 43, 247-255.	1.0	6
26	Personalized Therapy for Mycophenolate: Consensus Report by the International Association of Therapeutic Drug Monitoring and Clinical Toxicology. <i>Therapeutic Drug Monitoring</i> , 2021, 43, 150-200.	1.0	89
27	Cardiovascular Risk Factors are Inversely Associated With Omega-3 Polyunsaturated Fatty Acid Plasma Levels in Pediatric Kidney Transplant Recipients. , 2021, 31, 278-285.		4
28	Thoroughly Validated Bayesian Estimator and Limited Sampling Strategy for Dose Individualization of Ganciclovir and Valganciclovir in Pediatric Transplant Recipients. <i>Clinical Pharmacokinetics</i> , 2021, 60, 1449-1462.	1.6	5
29	Insulin secretion and action after pancreas transplantation. A retrospective single-center study. <i>Scandinavian Journal of Clinical and Laboratory Investigation</i> , 2021, 81, 365-370.	0.6	1
30	Low Immunization Rate in Kidney Transplant Recipients Also After Dose 2 of the BNT162b2 Vaccine: Continue to Keep Your Guard up!. <i>Transplantation</i> , 2021, 105, e80-e81.	0.5	16
31	Increased systemic exposure of once-daily tacrolimus in renal transplant recipients on marine omega-3 fatty acid supplementation. <i>Transplant International</i> , 2021, 34, 1322-1324.	0.8	0
32	Marine n-3 Polyunsaturated Fatty Acids and Bone Mineral Density in Kidney Transplant Recipients: A Randomized, Placebo-Controlled Trial. <i>Nutrients</i> , 2021, 13, 2361.	1.7	6
33	A snapshot of European registries on chronic kidney disease patients not on kidney replacement therapy. <i>Nephrology Dialysis Transplantation</i> , 2021, 37, 8-13.	0.4	7
34	Posttransplant Hypertension Matters!. <i>Transplantation</i> , 2021, 105, e150-e150.	0.5	0
35	The ERA-EDTA Registry Annual Report 2018: a summary. <i>CKJ: Clinical Kidney Journal</i> , 2021, 14, 107-123.	1.4	67
36	Elevated Terminal C5b-9 Complement Complex 10 Weeks Post Kidney Transplantation Was Associated With Reduced Long-Term Patient and Kidney Graft Survival. <i>Frontiers in Immunology</i> , 2021, 12, 738927.	2.2	4

#	ARTICLE	IF	CITATIONS
37	Deciphering transplant outcomes of expanded kidney allografts donated after controlled circulatory death in the current transplant era. A call for caution. <i>Transplant International</i> , 2021, 34, 2494-2506.	0.8	7
38	Timing of Kidney Clamping and Deceased Donor Kidney Transplant Outcomes. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2021, 16, 1704-1714.	2.2	4
39	A single Bayesian estimator for iohexol clearance estimation in ICU, liver failure and renal transplant patients. <i>British Journal of Clinical Pharmacology</i> , 2021, , .	1.1	3
40	Young deceased donor kidneys show a survival benefit over older donor kidneys in transplant recipients aged 20-50 years: a study by the ERA-EDTA Registry. <i>Nephrology Dialysis Transplantation</i> , 2020, 35, 534-543.	0.4	4
41	Why dose adjust systemic exposure when looking for associations with adverse events in tacrolimus-treated transplant recipients?. <i>British Journal of Clinical Pharmacology</i> , 2020, 86, 2535-2535.	1.1	1
42	Changes in clinical indicators related to the transition from dialysis to kidney transplantation data from the ERA-EDTA Registry. <i>CKJ: Clinical Kidney Journal</i> , 2020, 13, 188-198.	1.4	1
43	Reply to letter: "What about drug bioavailability in patients who had bariatric surgery and dependent on immunosuppressives?". <i>Obesity Reviews</i> , 2020, 21, e12954.	3.1	0
44	Cardiovascular remodelling in living kidney donors with reduced glomerular filtration rate: rationale and design of the CENS study. <i>Blood Pressure</i> , 2020, 29, 123-134.	0.7	2
45	Global variability analysis of mRNA and protein concentrations across and within human tissues. <i>NAR Genomics and Bioinformatics</i> , 2020, 2, lqz010.	1.5	40
46	Measured GFR by Utilizing Population Pharmacokinetic Methods to Determine Iohexol Clearance. <i>Kidney International Reports</i> , 2020, 5, 189-198.	0.4	13
47	Tacrolimus Area Under the Concentration Versus Time Curve Monitoring, Using Home-Based Volumetric Absorptive Capillary Microsampling. <i>Therapeutic Drug Monitoring</i> , 2020, 42, 407-414.	1.0	20
48	The Authors' Reply: Placental Pathology in Pregnancies After Kidney Transplantation. <i>Transplantation</i> , 2020, 104, e216-e216.	0.5	0
49	Fasting Status and Circadian Variation Must be Considered When Performing AUC-based Therapeutic Drug Monitoring of Tacrolimus in Renal Transplant Recipients. <i>Clinical and Translational Science</i> , 2020, 13, 1327-1335.	1.5	9
50	Five decades with grandparent donors: The Norwegian strategy and experience. <i>Pediatric Transplantation</i> , 2020, 24, e13751.	0.5	3
51	A Simplified Iohexol-Based Method to Measure Renal Function in Sheep Models of Renal Disease. <i>Biology</i> , 2020, 9, 259.	1.3	3
52	The ERA-EDTA Registry Annual Report 2017: a summary. <i>CKJ: Clinical Kidney Journal</i> , 2020, 13, 693-709.	1.4	65
53	P1679 HYPOMAGNEAEMIA AND HYPERGLYCAEMIA AFTER KIDNEY TRANSPLANTATION. <i>Nephrology Dialysis Transplantation</i> , 2020, 35, .	0.4	0
54	A Comparative Analysis of Cytochrome P450 Activities in Paired Liver and Small Intestinal Samples from Patients with Obesity. <i>Drug Metabolism and Disposition</i> , 2020, 48, 8-17.	1.7	27

#	ARTICLE	IF	CITATIONS
55	Endothelial function after pancreas transplantationâ€”A singleâ€”center observational study. <i>Clinical Transplantation</i> , 2020, 34, e13815.	0.8	0
56	Chronic Inhibition of CYP3A is Temporarily Reduced by Each Hemodialysis Session in Patients With Endâ€”Stage Renal Disease. <i>Clinical Pharmacology and Therapeutics</i> , 2020, 108, 866-873.	2.3	7
57	Severe Mycophenolate Intoxication in a Solid Organ Transplant Recipientâ€”No Intervention Actually Needed. <i>Transplantation Direct</i> , 2020, 6, e609.	0.8	0
58	The EKITE network (epidemiology in kidney transplantation - a European validated database): an initiative epidemiological and translational European collaborative research. <i>BMC Nephrology</i> , 2019, 20, 365.	0.8	11
59	The influence of bariatric surgery on oral drug bioavailability in patients with obesity: A systematic review. <i>Obesity Reviews</i> , 2019, 20, 1299-1311.	3.1	53
60	The European Renal Associationâ€”European Dialysis and Transplant Association (ERA-EDTA) Registry Annual Report 2016: a summary. <i>CKJ: Clinical Kidney Journal</i> , 2019, 12, 702-720.	1.4	178
61	Vitamin D as a risk factor for patient survival after kidney transplantation: A prospective observational cohort study. <i>Clinical Transplantation</i> , 2019, 33, e13517.	0.8	15
62	Efficacy and Safety of Empagliflozin in Renal Transplant Recipients With Posttransplant Diabetes Mellitus. <i>Diabetes Care</i> , 2019, 42, 1067-1074.	4.3	121
63	Contraceptive Choices and Counseling in Norwegian Female Renal Transplant Recipients. <i>Transplantation Proceedings</i> , 2019, 51, 470-474.	0.3	4
64	Evaluation of tools for annual capture of adherence to immunosuppressive medications after renal transplantation - a single-centre open prospective trial. <i>Transplant International</i> , 2019, 32, 614-625.	0.8	30
65	A287 Effect of Gastric Bypass and Very-Low Energy Diet on cardiometabolic risk factors. <i>Surgery for Obesity and Related Diseases</i> , 2019, 15, S114.	1.0	0
66	Tacrolimus Can Be Reliably Measured With Volumetric Absorptive Capillary Microsampling Throughout the Dose Interval in Renal Transplant Recipients. <i>Therapeutic Drug Monitoring</i> , 2019, 41, 607-614.	1.0	43
67	Beyond Survival in Solid Organ Transplantation: A Summary of Expert Presentations from the Sandoz 6th Standalone Transplantation Meeting, 2018. <i>Transplantation</i> , 2019, 103, S1-S13.	0.5	5
68	233.4: The Scandinavian exchange program: Ischemic time for imported kidneys in Norway and factors associated with long ischemic time.. <i>Transplantation</i> , 2019, 103, S50-S50.	0.5	0
69	A Fully Automated Method for the Determination of Serum Belatacept and Its Application in a Pharmacokinetic Investigation in Renal Transplant Recipients. <i>Therapeutic Drug Monitoring</i> , 2019, 41, 11-18.	1.0	11
70	Immunosuppression and Reproductive Health After Kidney Transplantation. <i>Transplantation</i> , 2019, 103, e325-e333.	0.5	30
71	Therapeutic Drug Monitoring of Tacrolimus-Personalized Therapy: Second Consensus Report. <i>Therapeutic Drug Monitoring</i> , 2019, 41, 261-307.	1.0	374
72	Effects of marine n-3 fatty acid supplementation in renal transplantation: A randomized controlled trial. <i>American Journal of Transplantation</i> , 2019, 19, 790-800.	2.6	16

#	ARTICLE	IF	CITATIONS
73	Pharmacokinetics of a novel, approved, 1.4µg intranasal naloxone formulation for reversal of opioid overdose—a randomized controlled trial. <i>Addiction</i> , 2019, 114, 859-867.	1.7	15
74	Validation of diagnostic utility of fasting plasma glucose and HbA1c in stable renal transplant recipients one year after transplantation. <i>BMC Nephrology</i> , 2019, 20, 12.	0.8	15
75	Trans-fatty Acids and Survival in Renal Transplantation. , 2019, 29, 169-180.		2
76	High tacrolimus clearance - a risk factor for development of interstitial fibrosis and tubular atrophy in the transplanted kidney: a retrospective single-center cohort study. <i>Transplant International</i> , 2019, 32, 257-269.	0.8	16
77	Pharmacokinetic models to assist the prescriber in choosing the best tacrolimus dose. <i>Pharmacological Research</i> , 2018, 130, 316-321.	3.1	34
78	Estimated glomerular filtration rate in stable older kidney transplant recipients—are present algorithms valid? A national cross-sectional cohort study. <i>Transplant International</i> , 2018, 31, 629-638.	0.8	6
79	Kidney allograft subclinical rejection modulates systemic inflammation measured by C-reactive protein at 1 year after transplantation. <i>Clinical Transplantation</i> , 2018, 32, e13196.	0.8	3
80	Inflammatory and related biomarkers are associated with post-transplant diabetes mellitus in kidney recipients: a retrospective study. <i>Transplant International</i> , 2018, 31, 510-519.	0.8	19
81	The Authors' Reply. <i>Transplantation</i> , 2018, 102, e43-e44.	0.5	0
82	The European Renal Association – European Dialysis and Transplant Association (ERA-EDTA) Registry Annual Report 2015: a summary. <i>CKJ: Clinical Kidney Journal</i> , 2018, 11, 108-122.	1.4	169
83	Determination of Tacrolimus Concentration and Protein Expression of P-Glycoprotein in Single Human Renal Core Biopsies. <i>Therapeutic Drug Monitoring</i> , 2018, 40, 292-300.	1.0	10
84	A Limited Sampling Strategy to Estimate Exposure of Everolimus in Whole Blood and Peripheral Blood Mononuclear Cells in Renal Transplant Recipients Using Population Pharmacokinetic Modeling and Bayesian Estimators. <i>Clinical Pharmacokinetics</i> , 2018, 57, 1459-1469.	1.6	12
85	Outcomes in Pancreas Transplantation With Exocrine Drainage Through a Duodenoduodenostomy Versus Duodenojejunostomy. <i>American Journal of Transplantation</i> , 2018, 18, 154-162.	2.6	26
86	Development of Kidney Transplant Fibrosis Is Inversely Associated With Plasma Marine Fatty Acid Level. , 2018, 28, 118-124.		6
87	First Scandinavian Protocol for Controlled Donation After Circulatory Death Using Normothermic Regional Perfusion. <i>Transplantation Direct</i> , 2018, 4, e366.	0.8	23
88	SP755MARINE n-3 FATTY ACID SUPPLEMENTATION INCREASE TACROLIMUS EXPOSURE IN RENAL TRANSPLANT RECIPIENTS. <i>Nephrology Dialysis Transplantation</i> , 2018, 33, i603-i603.	0.4	0
89	A Simple Strategy for Diagnosis of PTDM in Stable Kidney Transplanted Patients. <i>Transplantation</i> , 2018, 102, S83.	0.5	0
90	A Limited Sampling Strategy to Estimate Whole Blood and Intra-lymphocyte Exposure of Everolimus in Renal Transplant Recipients using Population Pharmacokinetic Modeling and Bayesian Estimators. <i>Transplantation</i> , 2018, 102, S92.	0.5	0

#	ARTICLE	IF	CITATIONS
91	High-Dose Fish Oil Supplementation Increase Tacrolimus Exposure in Stable Renal Transplant Recipients. <i>Transplantation</i> , 2018, 102, S599.	0.5	0
92	Outcomes of Kidney Transplantation in Former Non Kidney Solid Organ Transplant. <i>Transplantation</i> , 2018, 102, S85.	0.5	0
93	High Tacrolimus Clearance – A Risk Factor for Development of Interstitial Fibrosis and Tubular Atrophy in the Transplanted Kidney. <i>Transplantation</i> , 2018, 102, S364.	0.5	0
94	Preserved Insulin Sensitivity and Kidney Function One Year After Successful Pancreas Transplantation. <i>Transplantation</i> , 2018, 102, S751.	0.5	1
95	Adherence to Immunosuppressive Medications in Renal Transplant Recipients – Different Tools Capture Different Patients. <i>Transplantation</i> , 2018, 102, S282.	0.5	2
96	Arterial stiffness is associated with visceral fat mass in kidney transplanted patients – A nationwide cohort study. <i>Clinical Transplantation</i> , 2018, 32, e13341.	0.8	3
97	Preserved insulin secretion and kidney function in recipients with functional pancreas grafts 1 year after transplantation: a single-center prospective observational study. <i>European Journal of Endocrinology</i> , 2018, 179, 251-259.	1.9	7
98	SP736MARINE N-3 POLYUNSATURATED FATTY ACIDS AND BONE DENSITY IN KIDNEY TRANSPLANTATION: A DOUBLE-BLINDED, RANDOMIZED, PLACEBO-CONTROLLED TRIAL. <i>Nephrology Dialysis Transplantation</i> , 2018, 33, i596-i596.	0.4	0
99	SP744MARINE n-3 FATTY ACID SUPPLEMENTATION REDUCES PLASMA TRIGLYCERIDES & IMPROVES FLOW MEDIATED DILATATION IN RENAL TRANSPLANT RECIPIENTS. <i>Nephrology Dialysis Transplantation</i> , 2018, 33, i599-i599.	0.4	0
100	SP751MARINE n-3 FATTY ACID SUPPLEMENTATION REDUCES INFLAMMATION & PREVENTS RENAL GRAFT FIBROSIS. <i>Nephrology Dialysis Transplantation</i> , 2018, 33, i601-i601.	0.4	0
101	Paricalcitol supplementation during the first year after kidney transplantation does not affect calcification propensity score. <i>BMC Nephrology</i> , 2018, 19, 212.	0.8	5
102	Plasma n-6 Polyunsaturated Fatty Acid Levels and Survival in Renal Transplantation. , 2018, 28, 333-339.		1
103	Small effort, high impact: Focus on physical activity improves oxygen uptake ($VO_2\text{peak}$), quality of life, and mental health after pediatric renal transplantation. <i>Pediatric Transplantation</i> , 2018, 22, e13242.	0.5	6
104	Impact of body weight, low energy diet and gastric bypass on drug bioavailability, cardiovascular risk factors and metabolic biomarkers: protocol for an open, non-randomised, three-armed single centre study (COCKTAIL). <i>BMJ Open</i> , 2018, 8, e021878.	0.8	17
105	Inflammation in Early Kidney Allograft Surveillance Biopsies With and Without Associated Tubulointerstitial Chronic Damage as a Predictor of Fibrosis Progression and Development of De Novo Donor Specific Antibodies. <i>Transplantation</i> , 2017, 101, 1410-1415.	0.5	38
106	Collectin Liver 1 and Collectin Kidney 1 of the Lectin Complement Pathway Are Associated With Mortality After Kidney Transplantation. <i>American Journal of Transplantation</i> , 2017, 17, 265-271.	2.6	12
107	The CYP3A biomarker 4 β -hydroxycholesterol does not improve tacrolimus dose predictions early after kidney transplantation. <i>British Journal of Clinical Pharmacology</i> , 2017, 83, 1457-1465.	1.1	19
108	Exposure to Mycophenolate and Fatherhood. <i>Transplantation</i> , 2017, 101, e214-e217.	0.5	56

#	ARTICLE	IF	CITATIONS
109	Costimulation Blockade: America First, Canada Second – What About Norway?. American Journal of Transplantation, 2017, 17, 2230.	2.6	0
110	High Tacrolimus Clearance Is a Risk Factor for Acute Rejection in the Early Phase After Renal Transplantation. Transplantation, 2017, 101, e273-e279.	0.5	40
111	Associations Between Posttransplantation Diabetes Mellitus and Renal Graft Survival. Transplantation, 2017, 101, 1282-1289.	0.5	29
112	Response to: –Response to: Bodyweight –adjustments introduce significant correlations between CYP3A metrics and tacrolimus clearance –™. British Journal of Clinical Pharmacology, 2017, 83, 1357-1358.	1.1	1
113	Bodyweight –adjustments introduce significant correlations between CYP3A metrics and tacrolimus clearance. British Journal of Clinical Pharmacology, 2017, 83, 1350-1352.	1.1	5
114	A rapid and sustained improvement of calcification propensity score (serum T₅₀) after successful kidney transplantation: Reanalysis of a randomized controlled trial of ibandronate. Clinical Transplantation, 2017, 31, e13131.	0.8	4
115	Recovery of CYP3A Phenotype after Kidney Transplantation. Drug Metabolism and Disposition, 2017, 45, 1260-1265.	1.7	1
116	Tacrolimus and mycophenolate regimen and subclinical tubulo-interstitial inflammation in low immunological risk renal transplants. Transplant International, 2017, 30, 1119-1131.	0.8	10
117	Mycophenolate Acid and Balancing the Risk for Male Allograft Recipients. Transplantation, 2017, 101, e39.	0.5	3
118	How to Report and Interpret Bioequivalence Data in Solid Organ Transplant Recipients. Transplantation, 2017, 101, e347.	0.5	0
119	Haptoglobin 2-2 Genotype, Patient, and Graft Survival in Renal Transplant Recipients. Progress in Transplantation, 2017, 27, 386-391.	0.4	0
120	Risk factors for exertional rhabdomyolysis with renal stress. BMJ Open Sport and Exercise Medicine, 2017, 3, e000241.	1.4	9
121	Estimating Glomerular Filtration Rate in Kidney Transplant Recipients: Comparing a Novel Equation With Commonly Used Equations in this Population. Transplantation Direct, 2017, 3, e332.	0.8	17
122	Plasma Levels of Marine n-3 Fatty Acids Are Inversely Correlated With Proinflammatory Markers sTNFR1 and IL-6 in Renal Transplant Recipients. , 2017, 27, 161-168.		8
123	Visceral fat is strongly associated with post –transplant diabetes mellitus and glucose metabolism 1 –year after kidney transplantation. Clinical Transplantation, 2017, 31, e12869.	0.8	10
124	Individualizing Transplant Therapy. , 2017, , 255-279.		2
125	The European Renal Association – European Dialysis and Transplant Association Registry Annual Report 2014: a summary. CKJ: Clinical Kidney Journal, 2017, 10, 154-169.	1.4	64
126	Novel decay dynamics revealed for virus-mediated drug activation in cytomegalovirus infection. PLoS Pathogens, 2017, 13, e1006299.	2.1	12

#	ARTICLE	IF	CITATIONS
127	Prediction of Fat-Free Mass in Kidney Transplant Recipients. <i>Therapeutic Drug Monitoring</i> , 2016, 38, 439-446.	1.0	3
128	Serum Calcification Propensity Is a Strong and Independent Determinant of Cardiac and All-Cause Mortality in Kidney Transplant Recipients. <i>American Journal of Transplantation</i> , 2016, 16, 204-212.	2.6	74
129	Complexity of Host Micro-RNA Response to Cytomegalovirus Reactivation After Organ Transplantation. <i>American Journal of Transplantation</i> , 2016, 16, 650-660.	2.6	6
130	Low target tacrolimus in de novo standard risk renal transplant recipients: A single centre experience. <i>Nephrology</i> , 2016, 21, 821-827.	0.7	7
131	Measuring senescence rates of patients with end-stage renal disease while accounting for population heterogeneity: an analysis of data from the ERA-EDTA Registry. <i>Annals of Epidemiology</i> , 2016, 26, 773-779.	0.9	1
132	Low level of MAp44, an inhibitor of the lectin complement pathway, and long-term graft and patient survival; a cohort study of 382 kidney recipients. <i>BMC Nephrology</i> , 2016, 17, 148.	0.8	11
133	Resolution of Calciphylaxis After Urgent Kidney Transplantation in 3 Patients With End-Stage Kidney Failure. <i>Transplantation Direct</i> , 2016, 2, e113.	0.8	12
134	Mortality risk in post-transplantation diabetes mellitus based on glucose and HbA1c diagnostic criteria. <i>Transplant International</i> , 2016, 29, 568-578.	0.8	43
135	Plasma n-3 Polyunsaturated Fatty Acids and Bone Mineral Density in Renal Transplant Recipients. , 2016, 26, 196-203.		6
136	Lessons Learned From a Randomized Study of Oral Valganciclovir Versus Parenteral Ganciclovir Treatment of Cytomegalovirus Disease in Solid Organ Transplant Recipients: The VICTOR Trial. <i>Clinical Infectious Diseases</i> , 2016, 62, 1154-1160.	2.9	24
137	GLP-1 Restores Altered Insulin and Glucagon Secretion in Posttransplantation Diabetes. <i>Diabetes Care</i> , 2016, 39, 617-624.	4.3	46
138	Plasma levels of marine n-3 fatty acids and cardiovascular risk markers in renal transplant recipients. <i>European Journal of Clinical Nutrition</i> , 2016, 70, 824-830.	1.3	12
139	Improved Tacrolimus Target Concentration Achievement Using Computerized Dosing in Renal Transplant Recipients: A Prospective, Randomized Study. <i>Transplantation</i> , 2015, 99, 2158-2166.	0.5	77
140	Visceral fat is better related to impaired glucose metabolism than body mass index after kidney transplantation. <i>Transplant International</i> , 2015, 28, 1162-1171.	0.8	26
141	Aortic Stiffness in a Mortality Risk Calculator for Kidney Transplant Recipients. <i>Transplantation</i> , 2015, 99, 1730-1737.	0.5	42
142	Closer to the Site of Action. <i>Therapeutic Drug Monitoring</i> , 2015, 37, 675-680.	1.0	10
143	SP465LONG-TERM MORTALITY IN KIDNEY TRANSPLANT PATIENTS WITH PTDM IS BETTER PREDICTED BY GLUCOSE CRITERIA THAN WITH HBA1C CRITERIA. <i>Nephrology Dialysis Transplantation</i> , 2015, 30, iii533-iii534.	0.4	0
144	Hcmv-miR-UL22A-5p: A Biomarker in Transplantation With Broad Impact on Host Gene Expression and Potential Immunological Implications. <i>American Journal of Transplantation</i> , 2015, 15, 1893-1902.	2.6	28

#	ARTICLE	IF	CITATIONS
145	Limitations of Hemoglobin A1c for the Diagnosis of Posttransplant Diabetes Mellitus. <i>Transplantation</i> , 2015, 99, 629-635.	0.5	29
146	Increased Osteoprotegerin Predicts Poor Virological Outcome During Anticytomegalovirus Therapy in Solid Organ Transplant Recipients. <i>Transplantation</i> , 2015, 99, 100-105.	0.5	6
147	Use of Generic Tacrolimus in Elderly Renal Transplant Recipients. <i>Transplantation</i> , 2015, 99, 528-532.	0.5	42
148	Short-term efficacy and safety of sitagliptin treatment in long-term stable renal recipients with new-onset diabetes after transplantation. <i>Nephrology Dialysis Transplantation</i> , 2014, 29, 926-933.	0.4	78
149	More Potent Lipid-Lowering Effect by Rosuvastatin Compared With Fluvastatin in Everolimus-Treated Renal Transplant Recipients. <i>Transplantation</i> , 2014, 97, 1266-1271.	0.5	16
150	Importance of hematocrit for a tacrolimus target concentration strategy. <i>European Journal of Clinical Pharmacology</i> , 2014, 70, 65-77.	0.8	92
151	Secreted Wnt Antagonists During Eradication of Cytomegalovirus Infection in Solid Organ Transplant Recipients. <i>American Journal of Transplantation</i> , 2014, 14, 210-215.	2.6	12
152	Improved prediction of tacrolimus concentrations early after kidney transplantation using theory-based pharmacokinetic modelling. <i>British Journal of Clinical Pharmacology</i> , 2014, 78, 509-523.	1.1	67
153	Uric acid and clinical correlates of endothelial function in kidney transplant recipients. <i>Clinical Transplantation</i> , 2014, 28, 1167-1176.	0.8	5
154	The influence of CYP3A, PPARA, and POR genetic variants on the pharmacokinetics of tacrolimus and cyclosporine in renal transplant recipients. <i>European Journal of Clinical Pharmacology</i> , 2014, 70, 685-693.	0.8	107
155	New algorithm for valganciclovir dosing in pediatric solid organ transplant recipients. <i>Pediatric Transplantation</i> , 2014, 18, 103-111.	0.5	44
156	Long-term effects of gastric bypass and duodenal switch on systemic exposure of atorvastatin. <i>Surgical Endoscopy and Other Interventional Techniques</i> , 2013, 27, 2094-2101.	1.3	34
157	UGT1A1*28 is Associated with Decreased Systemic Exposure of Atorvastatin Lactone. <i>Molecular Diagnosis and Therapy</i> , 2013, 17, 233-237.	1.6	19
158	Inclusion of CYP3A5 genotyping in a nonparametric population model improves dosing of tacrolimus early after transplantation. <i>Transplant International</i> , 2013, 26, 1198-1207.	0.8	60
159	Impact of OATP1B1, MDR1, and CYP3A4 Expression in Liver and Intestine on Interpatient Pharmacokinetic Variability of Atorvastatin in Obese Subjects. <i>Clinical Pharmacology and Therapeutics</i> , 2013, 93, 275-282.	2.3	82
160	Virologic Suppression Measured by a Cytomegalovirus (CMV) DNA Test Calibrated to the World Health Organization International Standard Is Predictive of CMV Disease Resolution in Transplant Recipients. <i>Clinical Infectious Diseases</i> , 2013, 56, 1546-1553.	2.9	79
161	Long-term outcomes after cyclosporine or mycophenolate withdrawal in kidney transplantation – results from an aborted trial. <i>Clinical Transplantation</i> , 2013, 27, E151-6.	0.8	13
162	Endothelial Dysfunction Is Associated With Graft Loss in Renal Transplant Recipients. <i>Transplantation</i> , 2013, 95, 733-739.	0.5	12

#	ARTICLE	IF	CITATIONS
163	Updated International Consensus Guidelines on the Management of Cytomegalovirus in Solid-Organ Transplantation. <i>Transplantation</i> , 2013, 96, 333-360.	0.5	651
164	Characterization of Cytomegalovirus Disease in Solid Organ Transplant Recipients by Markers of Inflammation in Plasma. <i>PLoS ONE</i> , 2013, 8, e60767.	1.1	8
165	Evaluation of Organic Anion-Transporting Polypeptide 1B1 and CYP3A4 Activities in Primary Human Hepatocytes and HepaRG Cells Cultured in a Dynamic Three-Dimensional Bioreactor System. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2012, 343, 145-156.	1.3	20
166	The Concentration of Cyclosporine Metabolites Is Significantly Lower in Kidney Transplant Recipients With Diabetes Mellitus. <i>Therapeutic Drug Monitoring</i> , 2012, 34, 38-45.	1.0	31
167	Cyclosporine A- and Tacrolimus-Mediated Inhibition of CYP3A4 and CYP3A5 In Vitro. <i>Drug Metabolism and Disposition</i> , 2012, 40, 655-661.	1.7	75
168	Treatment of Cytomegalovirus Disease in Solid Organ Transplant Recipients. <i>Transplantation</i> , 2012, 94, 1060-1065.	0.5	16
169	A 1-Year Randomized, Double-Blind, Placebo-Controlled Study of Intravenous Ibandronate on Bone Loss Following Renal Transplantation. <i>American Journal of Transplantation</i> , 2012, 12, 3316-3325.	2.6	49
170	A drug safety evaluation of everolimus in kidney transplantation. <i>Expert Opinion on Drug Safety</i> , 2012, 11, 1013-1022.	1.0	19
171	Urinary proteomic shotgun approach for identification of potential acute rejection biomarkers in renal transplant recipients. <i>Transplantation Research</i> , 2012, 1, 9.	1.5	23
172	Analysis and clinical correlation of genetic variation in cytomegalovirus. <i>Transplant Infectious Disease</i> , 2012, 14, 132-140.	0.7	41
173	Atorvastatin Metabolite Measurements as a Diagnostic Tool for Statin-Induced Myopathy. <i>Molecular Diagnosis and Therapy</i> , 2011, 15, 221-227.	1.6	19
174	The Clinical Utility of Whole Blood Versus Plasma Cytomegalovirus Viral Load Assays for Monitoring Therapeutic Response. <i>Transplantation</i> , 2011, 91, 231-236.	0.5	87
175	Incidence and Outcomes of Ganciclovir-Resistant Cytomegalovirus Infections in 1244 Kidney Transplant Recipients. <i>Transplantation</i> , 2011, 92, 217-223.	0.5	97
176	Response to Letter About Intensity of Immunosuppressive Therapy on Outcome of Treatment for CMV Disease. <i>American Journal of Transplantation</i> , 2011, 11, 1103-1104.	2.6	0
177	OATP1B1/1B3 activity in plated primary human hepatocytes over time in culture. <i>Biochemical Pharmacology</i> , 2011, 82, 1219-1226.	2.0	35
178	No change in insulin sensitivity in renal transplant recipients converted from standard to once-daily prolonged release tacrolimus. <i>Nephrology Dialysis Transplantation</i> , 2011, 26, 3767-3772.	0.4	13
179	RAPID BIOMARKER DISCOVERY IN TRANSPLANTATION BY URINARY PROTEOMICS UTILIZING ACCELERATED 18O-LABELING. <i>Transplantation</i> , 2010, 90, 531.	0.5	0
180	International Consensus Guidelines on the Management of Cytomegalovirus in Solid Organ Transplantation. <i>Transplantation</i> , 2010, 89, 779-795.	0.5	898

#	ARTICLE	IF	CITATIONS
181	Effects of the Intensity of Immunosuppressive Therapy on Outcome of Treatment for CMV Disease in Organ Transplant Recipients. <i>American Journal of Transplantation</i> , 2010, 10, 1881-1888.	2.6	76
182	Hydrophilic interaction liquid chromatography-CE separation in urinary proteomics – Minimizing variability through improved downstream workflow compatibility. <i>Journal of Separation Science</i> , 2010, 33, 864-872.	1.3	12
183	Accelerated 18O-labeling in urinary proteomics. <i>Journal of Chromatography A</i> , 2010, 1217, 8241-8248.	1.8	6
184	Significant Increase in Systemic Exposure of Atorvastatin After Biliopancreatic Diversion With Duodenal Switch. <i>Clinical Pharmacology and Therapeutics</i> , 2010, 87, 699-705.	2.3	39
185	Cyclosporine A, but Not Tacrolimus, Shows Relevant Inhibition of Organic Anion-Transporting Protein 1B1-Mediated Transport of Atorvastatin. <i>Drug Metabolism and Disposition</i> , 2010, 38, 1499-1504.	1.7	127
186	IN VIVO VIRAL MICRORNA PROFILING IN A LARGE COHORT OF TRANSPLANT PATIENTS WITH CMV DISEASE. <i>Transplantation</i> , 2010, 90, 27.	0.5	0
187	Development of a Population Pharmacokinetic Model for Atorvastatin Acid and Its Lactone Metabolite. <i>Clinical Pharmacokinetics</i> , 2010, 49, 693-702.	1.6	20
188	Cytotoxicity of atorvastatin and simvastatin on primary rainbow trout (<i>Oncorhynchus mykiss</i>) hepatocytes. <i>Toxicology in Vitro</i> , 2010, 24, 1610-1618.	1.1	34
189	Valganciclovir for the prevention and treatment of CMV in solid organ transplant recipients. <i>Expert Opinion on Pharmacotherapy</i> , 2010, 11, 1159-1166.	0.9	12
190	Computer-Assisted Cyclosporine Dosing Performs Better Than Traditional Dosing in Renal Transplant Recipients: Results of a Pilot Study. <i>Therapeutic Drug Monitoring</i> , 2010, 32, 152-158.	1.0	15
191	Impact of Genetic Polymorphisms in Cytomegalovirus Glycoprotein B on Outcomes in Solid Organ Transplant Recipients with Cytomegalovirus Disease. <i>Clinical Infectious Diseases</i> , 2009, 49, 1160-1166.	2.9	96
192	An Assessment of Herpesvirus Co-infections in Patients with CMV Disease: Correlation with Clinical and Virologic Outcomes. <i>American Journal of Transplantation</i> , 2009, 9, 374-381.	2.6	70
193	Long-Term Outcomes of CMV Disease Treatment with Valganciclovir Versus IV Ganciclovir in Solid Organ Transplant Recipients. <i>American Journal of Transplantation</i> , 2009, 9, 1205-1213.	2.6	161
194	Significantly Altered Systemic Exposure to Atorvastatin Acid Following Gastric Bypass Surgery in Morbidly Obese Patients. <i>Clinical Pharmacology and Therapeutics</i> , 2009, 86, 311-318.	2.3	73
195	Calcineurin inhibitor effects on glucose metabolism and endothelial function following renal transplantation. <i>Clinical Transplantation</i> , 2009, 23, 511-518.	0.8	17
196	Didanosine ester prodrugs: Synthesis, albumin binding properties and pharmacokinetic studies in rats. <i>European Journal of Medicinal Chemistry</i> , 2009, 44, 3874-3879.	2.6	5
197	A Population Pharmacokinetic Model of Cyclosporin Applicable for Assisting Dose Management of Kidney Transplant Recipients. <i>Clinical Pharmacokinetics</i> , 2009, 48, 615-623.	1.6	18
198	Rimonabant Affects Cyclosporine A, but Not Tacrolimus Pharmacokinetics in Renal Transplant Recipients. <i>Transplantation</i> , 2009, 87, 1221-1224.	0.5	9

#	ARTICLE	IF	CITATIONS
199	Cytomegalovirus resistance in solid organ transplant recipients treated with intravenous ganciclovir or oral valganciclovir. <i>Antiviral Therapy</i> , 2009, 14, 697-704.	0.6	86
200	Statin induced myotoxicity: The lactone forms are more potent than the acid forms in human skeletal muscle cells in vitro. <i>European Journal of Pharmaceutical Sciences</i> , 2008, 33, 317-325.	1.9	110
201	Reduced Elimination of Cyclosporine A in Elderly (>65 Years) Kidney Transplant Recipients. <i>Transplantation</i> , 2008, 86, 1379-1383.	0.5	49
202	Declining Intracellular T-Lymphocyte Concentration of Cyclosporine A Precedes Acute Rejection in Kidney Transplant Recipients. <i>Transplantation</i> , 2008, 85, 179-184.	0.5	60
203	Endothelial Function in Renal Transplant Recipients is Associated with Circulating Nitric Oxide, ACE Inhibitor Use and Time After Transplantation. <i>Vascular Disease Prevention</i> , 2008, 3, 229-234.	0.2	0
204	Cinacalcet's effect on the pharmacokinetics of tacrolimus, cyclosporine and mycophenolate in renal transplant recipients. <i>Nephrology Dialysis Transplantation</i> , 2007, 23, 1048-1053.	0.4	42
205	The impact of short-term ciclosporin A treatment on insulin secretion and insulin sensitivity in man. <i>Nephrology Dialysis Transplantation</i> , 2007, 22, 1743-1749.	0.4	34
206	Determination of ganciclovir in different matrices from solid organ transplanted patients treated with a wide range of concomitant drugs. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2007, 43, 1039-1044.	1.4	17
207	Determination of ciclosporin A and its six main metabolites in isolated T-lymphocytes and whole blood using liquid chromatography-tandem mass spectrometry. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2007, 852, 345-352.	1.2	35
208	Oral Valganciclovir Is Noninferior to Intravenous Ganciclovir for the Treatment of Cytomegalovirus Disease in Solid Organ Transplant Recipients. <i>American Journal of Transplantation</i> , 2007, 7, 2106-2113.	2.6	366
209	Calcineurin Inhibitor Avoidance with Daclizumab, Mycophenolate Mofetil, and Prednisolone in DR-Matched de Novo Kidney Transplant Recipients. <i>Transplantation</i> , 2006, 82, 62-68.	0.5	41
210	Endothelial Function in Renal Transplant Recipients is Associated with Circulating Nitric Oxide, ACE Inhibitor Use and Time After Transplantation. <i>Vascular Disease Prevention</i> , 2006, 3, 229-234.	0.2	2
211	Association between insulin resistance and endothelial dysfunction in renal transplant recipients. <i>Clinical Transplantation</i> , 2006, 20, 195-199.	0.8	9
212	Exposure of atorvastatin is unchanged but lactone and acid metabolites are increased several-fold in patients with atorvastatin-induced myopathy. <i>Clinical Pharmacology and Therapeutics</i> , 2006, 79, 532-539.	2.3	119
213	Combined Therapy with Atorvastatin and Calcineurin Inhibitors: No Interactions with Tacrolimus. <i>American Journal of Transplantation</i> , 2005, 5, 2236-2243.	2.6	132
214	Atorvastatin does not affect the pharmacokinetics of cyclosporine in renal transplant recipients. <i>European Journal of Clinical Pharmacology</i> , 2005, 61, 59-62.	0.8	5
215	New-Onset Posttransplantation Diabetes Mellitus: Insulin Resistance or Insulinopenia? Impact of Immunosuppressive Drugs, Cytomegalovirus and Hepatitis C Virus Infection. <i>Current Diabetes Reviews</i> , 2005, 1, 1-10.	0.6	38
216	Short-term treatment with rosiglitazone improves glucose tolerance, insulin sensitivity and endothelial function in renal transplant recipients. <i>Nephrology Dialysis Transplantation</i> , 2005, 20, 413-418.	0.4	57

#	ARTICLE	IF	CITATIONS
217	Substantially elevated levels of atorvastatin and metabolites in cyclosporine-treated renal transplant recipients. <i>Clinical Pharmacology and Therapeutics</i> , 2004, 76, 388-391.	2.3	56
218	Fluvastatin and fluvastatin extended release: a clinical and safety profile. <i>Expert Review of Cardiovascular Therapy</i> , 2004, 2, 641-652.	0.6	15
219	Fluvastatin reduces atherogenic lipids without any effect on native endothelial function early after kidney transplantation. <i>Clinical Transplantation</i> , 2003, 17, 385-390.	0.8	15
220	Interactions Between Cyclosporin and Lipid-Lowering Drugs. <i>Drugs</i> , 2003, 63, 367-378.	4.9	126
221	Pre-emptive therapy of CMVpp65 antigen positive renal transplant recipients with oral ganciclovir: a randomized, comparative study. <i>Nephrology Dialysis Transplantation</i> , 2003, 18, 1899-1908.	0.4	52
222	Desacetyl-Diltiazem Displays Several-fold Higher Affinity to CYP2D6 Compared with CYP3A4. <i>Drug Metabolism and Disposition</i> , 2002, 30, 1-3.	1.7	38
223	Early intervention with a potent endothelin-A/endothelin-B receptor antagonist aggravates left ventricular remodeling after myocardial infarction in rats. <i>Basic Research in Cardiology</i> , 2002, 97, 239-247.	2.5	21
224	Coadministration of grapefruit juice increases systemic exposure of diltiazem in healthy volunteers. <i>European Journal of Clinical Pharmacology</i> , 2002, 58, 515-520.	0.8	51
225	Better microvascular function on long-term treatment with lisinopril than with nifedipine in renal transplant recipients. <i>Nephrology Dialysis Transplantation</i> , 2001, 16, 1465-1470.	0.4	24
226	Atorvastatin improves endothelial function in renal transplant recipients. <i>Nephrology Dialysis Transplantation</i> , 2001, 16, 1920-1924.	0.4	52
227	Bilateral Pharmacokinetic Interaction Between Cyclosporine A and Atorvastatin in Renal Transplant Recipients. <i>American Journal of Transplantation</i> , 2001, 1, 382-386.	2.6	124
228	CYP2D6 is involved in O-demethylation of diltiazem. <i>European Journal of Clinical Pharmacology</i> , 2000, 56, 575-579.	0.8	34
229	Each Administration of Cyclosporin A Enhances Skin Microvascular Reactivity in Renal Transplant Recipients. <i>Microvascular Research</i> , 2000, 60, 81-90.	1.1	15
230	Pharmacokinetic interactions between microemulsion formulated cyclosporine A and diltiazem in renal transplant recipients. <i>European Journal of Clinical Pharmacology</i> , 1999, 55, 383-387.	0.8	35
231	A simple and sensitive high-performance liquid chromatography assay of diltiazem and main metabolites in renal transplanted patients. <i>Clinica Chimica Acta</i> , 1999, 283, 63-75.	0.5	16
232	Nonspecific Microvascular Vasodilation during Iontophoresis Is Attenuated by Application of Hyperosmolar Saline. <i>Microvascular Research</i> , 1999, 58, 41-48.	1.1	44
233	GENE EXPRESSION OF THE RENAL ENDOTHELIN SYSTEM IN RENAL TRANSPLANT RECIPIENTS ON CYCLOSPORINE A BASED IMMUNOSUPPRESSION. <i>Transplantation</i> , 1999, 67, 1056-1060.	0.5	3
234	Quantification of mRNA levels of endothelin receptor subtypes and preproEndothelin-1 in renal needle biopsies by competitive reverse transcriptase polymerase chain reaction. <i>Scandinavian Journal of Clinical and Laboratory Investigation</i> , 1998, 58, 299-306.	0.6	1

#	ARTICLE	IF	CITATIONS
235	Pulmonary Hemodynamics and Plasma Endothelin-1 during Hypoxemia and Reoxygenation with Room Air or 100% Oxygen in a Piglet Model. <i>Pediatric Research</i> , 1998, 44, 843-849.	1.1	37
236	Diltiazem modulates cyclosporin A induced renal hemodynamic effects but not its effect on plasma endothelin-1. <i>Clinical Transplantation</i> , 1998, 12, 363-70.	0.8	13
237	Glipizide treatment of post-transplant diabetes does not interfere with cyclosporine pharmacokinetics in renal allograft recipients. <i>Clinical Transplantation</i> , 1998, 12, 553-6.	0.8	17